[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2020012587A - Anticuerpos anti-cd3 y usos de estos. - Google Patents

Anticuerpos anti-cd3 y usos de estos.

Info

Publication number
MX2020012587A
MX2020012587A MX2020012587A MX2020012587A MX2020012587A MX 2020012587 A MX2020012587 A MX 2020012587A MX 2020012587 A MX2020012587 A MX 2020012587A MX 2020012587 A MX2020012587 A MX 2020012587A MX 2020012587 A MX2020012587 A MX 2020012587A
Authority
MX
Mexico
Prior art keywords
antibodies
relates
present
specifically bind
tmeff2
Prior art date
Application number
MX2020012587A
Other languages
English (en)
Inventor
Francois Gaudet
Ronan Mcdaid
Chichi Huang
Jill Giles-Komar
Bradley Heidrich
Colleen Kane
Jennifer Nemeth-Seay
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2020012587A publication Critical patent/MX2020012587A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con anticuerpos que se unen específicamente al CD3; la presente invención se relaciona con anticuerpos que se unen específicamente al PSMA; la presente invención se relaciona con anticuerpos que se unen específicamente al CD3 y PSMA; la presente invención se relaciona con anticuerpos que se unen específicamente al IL1RAP; la presente invención se relaciona con anticuerpos que se unen específicamente al CD33; la presente invención se relaciona con anticuerpos que se unen específicamente al CD3 y IL1RAP; la presente invención se relaciona con anticuerpos que se unen específicamente al CD3 y CD33; la presente invención se relaciona con anticuerpos que se unen específicamente al TMEFF2; la presente invención se relaciona con anticuerpos que se unen específicamente al CD3 y TMEFF2; la presente invención se relaciona con fragmentos de los anticuerpos, polinucleótidos que codifican los anticuerpos o fragmentos de estos, y métodos de preparación y usos de estos.
MX2020012587A 2018-05-24 2019-05-21 Anticuerpos anti-cd3 y usos de estos. MX2020012587A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862676081P 2018-05-24 2018-05-24
PCT/IB2019/054188 WO2019224717A2 (en) 2018-05-24 2019-05-21 Anti-cd3 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2020012587A true MX2020012587A (es) 2021-04-28

Family

ID=67211773

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020012587A MX2020012587A (es) 2018-05-24 2019-05-21 Anticuerpos anti-cd3 y usos de estos.

Country Status (27)

Country Link
US (2) US11603405B2 (es)
EP (1) EP3802608A2 (es)
JP (2) JP7530299B2 (es)
KR (1) KR20210012007A (es)
CN (1) CN112912397A (es)
AR (1) AR115422A1 (es)
AU (1) AU2019274656A1 (es)
BR (1) BR112020023508A2 (es)
CA (1) CA3101271A1 (es)
CL (1) CL2020003033A1 (es)
CO (1) CO2020014506A2 (es)
CR (1) CR20200568A (es)
EA (1) EA202092847A1 (es)
EC (1) ECSP20075215A (es)
IL (1) IL278846A (es)
JO (1) JOP20200302A1 (es)
MA (1) MA52773A (es)
MX (1) MX2020012587A (es)
NI (1) NI202000089A (es)
PE (1) PE20210132A1 (es)
PH (1) PH12020551920A1 (es)
SA (1) SA520420631B1 (es)
SG (1) SG11202011270QA (es)
TW (1) TW202012443A (es)
UA (1) UA129050C2 (es)
UY (1) UY38245A (es)
WO (1) WO2019224717A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI835006B (zh) 2015-08-28 2024-03-11 美商亞穆尼克斯製藥公司 嵌合多肽組合體以及其製備及使用方法
CA3066918A1 (en) 2017-06-12 2018-12-20 Bluefin Biomedicine, Inc. Anti-il1rap antibodies and antibody drug conjugates
JOP20190116A1 (ar) * 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
US11746157B2 (en) 2018-05-24 2023-09-05 Janssen Biotech, Inc. PSMA binding agents and uses thereof
MX2020012589A (es) 2018-05-24 2021-01-29 Janssen Biotech Inc Anticuerpos anti-tmeff2 monoespecificos y multiespecificos y sus usos.
TWI838389B (zh) * 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
LT3823665T (lt) 2018-07-19 2024-02-26 Regeneron Pharmaceuticals, Inc. Chimeriniai antigeno receptoriai, pasižymintys specifiškumu bcma, ir jų panaudojimas
MX2021012767A (es) 2019-04-19 2021-11-18 Janssen Biotech Inc Metodos para tratar el cancer de prostata con un anticuerpo anti-psma/cd3.
CN114375302B (zh) 2019-07-26 2024-12-24 詹森生物科技公司 包含激肽释放酶相关肽酶2抗原结合结构域的蛋白质及其用途
IL295897A (en) * 2020-02-27 2022-10-01 Janssen Biotech Inc Materials and methods for modulating an immune response
US20210284731A1 (en) * 2020-03-13 2021-09-16 Janssen Biotech, Inc. Methods and materials for modulating an immune response
IL298444A (en) 2020-05-27 2023-01-01 Janssen Biotech Inc Proteins comprising cd3 antigen binding domains and uses thereof
MX2023001256A (es) 2020-07-29 2023-05-16 Janssen Biotech Inc Proteínas que comprenden dominios de unión al antígeno hla-g y sus usos.
US20230398147A1 (en) 2020-09-16 2023-12-14 Amgen Inc. Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer
TW202216784A (zh) * 2020-09-29 2022-05-01 大陸商信達生物製藥（蘇州）有限公司 抗ｃｄ３抗體以及其用途
US20240025992A1 (en) 2020-10-22 2024-01-25 Janssen Biotech, Inc. Proteins comprising delta-like ligand 3 (dll3) antigen binding domains and their uses
JP2024520338A (ja) 2021-05-21 2024-05-24 レオ ファーマ アクティーゼルスカブ 抗ｉｌ－１受容体アクセサリータンパク質抗体
KR20240049342A (ko) * 2021-08-27 2024-04-16 얀센 바이오테크 인코포레이티드 항-psma 항체 및 이의 용도
US20230073821A1 (en) * 2021-08-27 2023-03-09 International Business Machines Corporation Antigen-binding proteins targeting coronavirus (cov) variants
WO2023178645A1 (zh) * 2022-03-25 2023-09-28 嘉和生物药业有限公司 靶向cd3的抗体及其应用
TW202428613A (zh) 2022-09-21 2024-07-16 法商賽諾菲生物技術公司 人源化抗il-1r3抗體及使用方法
WO2024077044A1 (en) 2022-10-05 2024-04-11 Amgen Inc. Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
WO2024089551A1 (en) 2022-10-25 2024-05-02 Janssen Biotech, Inc. Msln and cd3 binding agents and methods of use thereof
WO2024126833A1 (en) * 2022-12-16 2024-06-20 Ichnos Sciences SA Cd47-il1rap bispecific antibodies

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
DE69233782D1 (de) 1991-12-02 2010-05-20 Medical Res Council Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
US5837242A (en) 1992-12-04 1998-11-17 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
ES2243007T3 (es) 1997-09-16 2005-11-16 Egea Biosciences Llc Sintesis quimica completa y sintesis de genes de genomas.
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN101940189A (zh) 2000-11-30 2011-01-12 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
JP2005538706A (ja) 2001-07-12 2005-12-22 ジェファーソン フーテ， スーパーヒト化抗体
AU2005282700A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
PL1999154T3 (pl) 2006-03-24 2013-03-29 Merck Patent Gmbh Skonstruowane metodami inżynierii heterodimeryczne domeny białkowe
EP2035456A1 (en) 2006-06-22 2009-03-18 Novo Nordisk A/S Production of bispecific antibodies
JP2010535032A (ja) 2007-07-31 2010-11-18 メディミューン，エルエルシー 多重特異性エピトープ結合性タンパク質およびその用途
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
CN101970730A (zh) 2007-12-19 2011-02-09 森托科尔奥索生物科技公司 通过融合到pⅨ或pⅦ来设计和生成人从头pⅨ噬菌体展示文库,载体、抗体及方法
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
JP2012505654A (ja) 2008-10-14 2012-03-08 ヤンセン バイオテツク，インコーポレーテツド 抗体をヒト化及び親和性成熟する方法
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
CA2796181C (en) 2010-04-20 2023-01-03 Genmab A/S Heterodimeric antibody fc-containing proteins and methods for production thereof
EP2635607B1 (en) 2010-11-05 2019-09-04 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
MX369220B (es) 2011-05-21 2019-10-31 Macrogenics Inc Moleculas que enlazan cd3 capaces de enlazar a cd3 humano y no humano.
CN109897103B (zh) 2011-11-04 2024-05-17 酵活英属哥伦比亚有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
JOP20200236A1 (ar) * 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
KR102239125B1 (ko) 2012-12-14 2021-04-12 오픈 모노클로날 테크놀로지, 인코포레이티드 인간 이디오타입을 갖는 설치류 항체를 인코딩하는 폴리뉴클레오티드 및 이를 포함하는 동물
UA119646C2 (uk) * 2013-07-05 2019-07-25 Ґенмаб А/С Гуманізоване антитіло, що зв`язується з сd3 людини
PL3736292T3 (pl) * 2013-12-17 2024-09-23 Genentech, Inc. Przeciwciała anty-CD3 i sposoby stosowania
RU2016151235A (ru) 2014-05-28 2018-06-28 Ф. Хоффманн-Ля Рош Аг Антитела, связывающиеся с cd3 эпсилон человека и обезьян циномолгус
EP2982693A1 (en) 2014-08-07 2016-02-10 Affimed Therapeutics AG CD3 binding domain
SI3247725T1 (sl) * 2015-01-23 2020-11-30 Sanofi Protitelesa proti-CD3, protitelesa proti -CD123 in bispecifična protitelesa, ki se specifično vežejo na CD3 in/ali CD123
CN108431042A (zh) 2015-11-02 2018-08-21 詹森药业有限公司 抗-il1rap抗体，结合il1rap和cd3的双特异性抗原结合分子及其用途
PT4050034T (pt) 2016-09-14 2024-05-27 Teneoone Inc Anticorpos de ligação a cd3
MA52632A (fr) * 2018-05-16 2021-09-15 Janssen Biotech Inc Anticorps bispécifiques bcma/cd3 et gprdc5d/cd3 aux fins d'utilisation dans le traitement du cancer
MX2020012589A (es) 2018-05-24 2021-01-29 Janssen Biotech Inc Anticuerpos anti-tmeff2 monoespecificos y multiespecificos y sus usos.
JOP20190116A1 (ar) 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
US11746157B2 (en) 2018-05-24 2023-09-05 Janssen Biotech, Inc. PSMA binding agents and uses thereof

Also Published As

Publication number Publication date
UA129050C2 (uk) 2025-01-01
CN112912397A (zh) 2021-06-04
MA52773A (fr) 2021-04-14
US20230322924A1 (en) 2023-10-12
KR20210012007A (ko) 2021-02-02
WO2019224717A9 (en) 2021-02-04
EP3802608A2 (en) 2021-04-14
BR112020023508A2 (pt) 2021-03-30
PH12020551920A1 (en) 2021-06-14
EA202092847A1 (ru) 2021-04-20
PE20210132A1 (es) 2021-01-19
WO2019224717A3 (en) 2020-03-05
AR115422A1 (es) 2021-01-20
CA3101271A1 (en) 2019-11-28
SG11202011270QA (en) 2020-12-30
JP7530299B2 (ja) 2024-08-07
US11603405B2 (en) 2023-03-14
JOP20200302A1 (ar) 2020-11-23
JP2024116190A (ja) 2024-08-27
CR20200568A (es) 2021-02-26
IL278846A (en) 2021-01-31
CL2020003033A1 (es) 2021-04-16
SA520420631B1 (ar) 2023-12-03
NI202000089A (es) 2021-01-21
WO2019224717A2 (en) 2019-11-28
TW202012443A (zh) 2020-04-01
US20200048349A1 (en) 2020-02-13
ECSP20075215A (es) 2020-12-31
UY38245A (es) 2019-11-29
CO2020014506A2 (es) 2020-12-10
AU2019274656A1 (en) 2020-11-26
JP2021524249A (ja) 2021-09-13

Similar Documents

Publication Publication Date Title
PH12020551920A1 (en) Anti-cd3 antibodies and uses thereof
PH12020551997A1 (en) Psma binding agents and uses thereof
PH12019502755A1 (en) Antibodies that specifically bind pd-1 and methods of use
PH12019502282A1 (en) Bispecific antibodies specifically binding to pd1 and lag3
JOP20190236A1 (ar) أجسام مضادة لـ ilt4 وشظايا ارتباط بمولد ضد
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
MX2018005550A (es) Anticuerpos que se unen especificamente a tim-3 y sus usos.
PH12017502019B1 (en) Heterodimeric antibodies that bind cd3 and tumor antigens
MX2021003704A (es) Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales.
CR20200171A (es) Contorsbodies 2 + 1 biespecíficos
EA201891582A1 (ru) Иммуностимулирующие гуманизированные моноклональные антитела против интерлейкина-2 человека и их слитые белки
PH12019502087A1 (en) Anti-par2 antibodies and uses thereof
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof